nach oben

Erschienen in:

20.11.2017 | Original Article

In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor that contains numerous osteoclasts formed from marrow-derived precursors through receptor activator of nuclear factor κ-B ligand (RANKL), an osteoclast differentiation factor expressed in neoplastic cells of GCTB. Denosumab, a fully human monoclonal antibody targeting RANKL, has recently been used for the treatment of GCTB, and superior treatment effects have been reported. The aim of this work was to elucidate the mechanism of action of denosumab, and the differences between denosumab and zoledronic acid at the level of GCTB cells. We isolated GCTB cells from 3 patients and separated them into osteoclasts, osteoclast precursors and proliferating spindle-shaped stromal cells (the true neoplastic component), and examined the action of denosumab on differentiation, survival and bone resorption activity of osteoclasts. Denosumab and zoledronic acid inhibited osteoclast differentiation from mononuclear cells containing osteoclast precursors. Zoledronic acid inhibited osteoclast survival, whereas an inhibitory effect of denosumab on osteoclast survival was not observed. The inhibitory effect on bone resorption by both agents was confirmed in culture on dentin slices. Furthermore, zoledronic acid showed dose-dependent inhibition of cell growth of neoplastic cells whereas denosumab had no inhibitory effect on these cells. Denosumab has an inhibitory effect on osteoclast differentiation, but no inhibitory effects on survival of osteoclasts or growth of neoplastic cells in GCTBs.

Wulling M, Engels C, Jesse N et al (2001) The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 127:467–474CrossRefPubMed

Stewart MJ, Richardson TR (1952) Giant cell tumor of bone. J Bone Joint Surg (Am Vol) 34-A:272–286

Raskin KA, Schwab JH, Mankin HJ et al (2013) Giant cell tumor of bone. J Am Acad Orthop Surg 21:118–126CrossRefPubMed

Chambers TJ, Fuller K, McSheehy PM et al (1985) The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J Pathol 145:297–305CrossRefPubMed

Kanehisa J, Izumo T, Takeuchi M et al (1991) In vitro bone resorption by isolated multinucleated giant cells from giant cell tumour of bone: light and electron microscopic study. Virchows Arch A Pathol Anat Histopathol 419:327–338CrossRefPubMed

Drake FH, Dodds RA, James IE et al (1996) Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271:12511–12516CrossRefPubMed

Huang L, Xu J, Wood DJ et al (2000) Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 156:761–767CrossRefPubMedPubMedCentral

Joyner CJ, Quinn JM, Triffitt JT et al (1992) Phenotypic characterisation of mononuclear and multinucleated cells of giant cell tumour of bone. Bone Miner 16:37–48CrossRefPubMed

Lau YS, Sabokbar A, Gibbons CL et al (2005) Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 36:945–954CrossRefPubMed

10.

Campanacci M, Baldini N, Boriani S et al (1987) Giant-cell tumor of bone. J Bone Joint Surg Am 69:106–114CrossRefPubMed

11.

Arbeitsgemeinschaft K, Becker WT, Dohle J et al (2008) Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 90:1060–1067CrossRef

12.

Mori Y, Tsuchiya H, Karita M et al (2000) Malignant transformation of a giant cell tumor 25 years after initial treatment. Clin Orthop Relat Res 381:185–191CrossRef

13.

Rock MG, Sim FH, Unni KK et al (1986) Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients. J Bone Joint Surg Am 68:1073–1079CrossRefPubMed

14.

Nascimento AG, Huvos AG, Marcove RC (1979) Primary malignant giant cell tumor of bone: a study of eight cases and review of the literature. Cancer 44:1393–1402CrossRefPubMed

15.

Bertoni F, Present D, Sudanese A et al (1988) Giant-cell tumor of bone with pulmonary metastases. Six case reports and a review of the literature. Clin Orthop Relat Res 237:275–285

16.

Kay RM, Eckardt JJ, Seeger LL et al (1994) Pulmonary metastasis of benign giant cell tumor of bone. Six histologically confirmed cases, including one of spontaneous regression. Clin Orthop Relat Res 302:219–230

17.

Nakashima T, Hayashi M, Takayanagi H (2012) New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab 23:582–590CrossRefPubMed

18.

Suda T, Takahashi N, Udagawa N et al (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357CrossRefPubMed

19.

Blair HC, Athanasou NA (2004) Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 19:189–199PubMed

20.

Shiotani A, Takami M, Itoh K et al (2002) Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. Anat Rec 268:137–146CrossRefPubMed

21.

Blackley HR, Wunder JS, Davis AM et al (1999) Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 81:811–820CrossRefPubMed

22.

XC Y, Xu M, Song RX et al (2010) Long-term outcome of giant cell tumors of bone around the knee treated by en bloc resection of tumor and reconstruction with prosthesis. Orthop Surg 2:211–217CrossRef

23.

Puthoor DK, Puthezhath K (2012) Management of giant cell tumor of bone: computerized tomography based selection strategy and approaching the lesion through the site of cortical break. Orthop Surg 4:76–82CrossRefPubMed

24.

Singh AS, Chawla NS, Chawla SP (2015) Giant-cell tumor of bone: treatment options and role of denosumab. Biologics 9:69–74PubMedPubMedCentral

25.

Tse LF, Wong KC, Kumta SM et al (2008) Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 42:68–73CrossRefPubMed

26.

Balke M, Campanacci L, Gebert C et al (2010) Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant cell tumour of bone. BMC Cancer 10:462CrossRefPubMedPubMedCentral

27.

Yang T, Zheng XF, Lin X et al (2013) Postoperative irrigation with bisphosphonates may reduce the recurrence of giant cell tumor of bone. Med Hypotheses 81:851–852CrossRefPubMed

28.

Gouin F, Rochwerger AR, Di Marco A et al (2014) Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone. Eur J Cancer 50:2425–2431CrossRefPubMed

29.

Bekker PJ, Holloway DL, Rasmussen AS et al (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066CrossRefPubMed

30.

Lacey DL, Boyle WJ, Simonet WS et al (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11:401–419CrossRefPubMed

31.

Thomas D, Henshaw R, Skubitz K et al (2010) Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 11:275–280CrossRefPubMed

32.

Lewiecki EM (2010) Clinical use of denosumab for the treatment for postmenopausal osteoporosis. Curr Med Res Opin 26:2807–2812CrossRefPubMed

33.

Morgan T, Atkins GJ, Trivett MK et al (2005) Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 167:117–128CrossRefPubMedPubMedCentral

34.

Roux S, Amazit L, Meduri G et al (2002) RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 117:210–216CrossRefPubMed

35.

Thomas DM (2012) RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol 24:397–403CrossRefPubMed

36.

Hakozaki M, Tajino T, Yamada H et al (2014) Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab. Diagn Pathol 9:111CrossRefPubMedPubMedCentral

37.

Yamagishi T, Kawashima H, Ogose A et al (2016) Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: a case report. Oncol Lett 11:243–246CrossRefPubMed

38.

van Beek E, Pieterman E, Cohen L et al (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108–111CrossRefPubMed

39.

Martin M, Bell R, Bourgeois H et al (2012) Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 18:4841–4849CrossRefPubMed

40.

Lipton A, Fizazi K, Stopeck AT et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092CrossRefPubMed

41.

Scagliotti GV, Hirsh V, Siena S et al (2012) Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 7:1823–1829CrossRefPubMed

42.

Branstetter DG, Nelson SD, Manivel JC et al (2012) Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 18:4415–4424CrossRefPubMed

43.

Cheng YY, Huang L, Lee KM et al (2004) Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 75:71–77CrossRefPubMed

44.

Nishisho T, Hanaoka N, Miyagi R et al (2015) Local administration of zoledronic acid for giant cell tumor of bone. Orthopedics 38:e25–e30CrossRefPubMed

45.

Salerno M, Avnet S, Alberghini M et al (2008) Histogenetic characterization of giant cell tumor of bone. Clin Orthop Relat Res 466:2081–2091CrossRefPubMedPubMedCentral

46.

Avnet S, Salerno M, Zini N et al (2013) Sustained autocrine induction and impaired negative feedback of osteoclastogenesis in CD14(+) cells of giant cell tumor of bone. Am J Pathol 182:1357–1366CrossRefPubMed

47.

Takami M, Takahashi N, Udagawa N et al (2000) Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Endocrinology 141:4711–4719CrossRefPubMed

48.

Agarwal A, Larsen BT, Buadu LD et al (2013) Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection. Case Rep Oncol Med 2013:496351PubMedPubMedCentral

49.

Akaike K, Suehara Y, Takagi T et al (2014) An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab. Skelet Radiol 43:1767–1772CrossRef

50.

Mattei TA, Ramos E, Rehman AA et al (2014) Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab. Spine J 14:e15–e21CrossRefPubMed

51.

Atkins J, Kostakis P, Vincent C et al (2006) RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 21:1339–1349CrossRefPubMed

52.

Liverani C, Mercatali L, Spadazzi C et al (2014) CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. Bone 66:214–222CrossRefPubMed

53.

Cheng YY, Huang L, Kumta SM et al (2003) Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration. Ultrastruct Pathol 27:385–391CrossRefPubMed

54.

Lau CP, Huang L, Wong KC et al (2013) Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neopastic cells of giant cell tumor of bone. Connect Tissue Res 54:439–449CrossRefPubMed

55.

Ueda T, Morioka H, Nishida Y et al (2015) Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol 26:2149–2154CrossRefPubMedPubMedCentral

56.

Akiyama T, Choong PF, Dass CR (2010) RANK-fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis 27:207–215CrossRefPubMed

57.

James IE, Dodds RA, Olivera DL et al (1996) Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J Bone Miner Res 11:1453–1460CrossRefPubMed

58.

Murata A, Fujita T, Kawahara N et al (2005) Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci 10:581–588CrossRefPubMed

Titel: In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid
Publikationsdatum: 20.11.2017
Erschienen in: Pathology & Oncology Research / Ausgabe 1/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0362-8

Springer Medizin

In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Genetic Variations of DNA Repair Genes in Breast Cancer

The Impact of Peritumoral Retraction Clefting & Intratumoral Eosinophils on Overall Survival in Oral Squamous Carcinoma Patients

Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer

DDR2 and IFITM1 Are Prognostic Markers in Gallbladder Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas

Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review

Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie